Business context and reporting period
The source filing is Trxade Group, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2017; this does not match the request metadata naming Scienture Holdings, Inc. Trxade operates a web-based marketplace connecting independent pharmacies with pharmaceutical suppliers. Its Westminster Pharmaceuticals distribution business was sold in December 2016 and is reported as discontinued operations.
Financial results and liquidity
- Third quarter: Revenue was $735,869, up 20% from $610,832 a year earlier. Gross profit was $735,869, with no cost of sales reported. Operating income was $89,615 versus an operating loss of $245,220; net income was $76,193 versus a net loss of $842,880, including a $547,403 discontinued-operations loss in 2016. Basic and diluted EPS were each reported as $0.00.
- Nine months: Revenue was $2,141,540, up 16% from $1,843,843. Operating income was $234,848 versus an operating loss of $953,076; net income was $149,077 versus a net loss of $2,317,075, including a $1,205,442 discontinued-operations loss in 2016. EPS was reported as $0.00.
- Expenses and margins: Nine-month operating expenses were $1,906,692, including $222,052 of stock-option expense. Operating margin was approximately 11% and net margin approximately 7%. Management attributed improved results mainly to higher platform and transition-fee revenue and lower employee cash compensation.
- Cash flow: Nine-month operating cash flow was positive $118,352, compared with negative $276,658 in 2016. Financing provided $40,299; cash increased $158,651 to $173,330. The filing attributes improved cash partly to increased customers and revenue, and reports $250,250 from stock issuance and warrant exercise.
- Balance sheet at September 30: Cash was $173,330; current assets were $531,599 and current liabilities $625,169, yielding working capital of negative $93,570. Total liabilities were $1,029,221 and shareholders’ deficit was $497,622. Current and long-term related-party notes were material; the balance sheet reports $251,725 of short-term related-party convertible notes, $222,552 of long-term related-party notes, and $181,500 of long-term convertible notes.
Changes, outlook, and risks
- Compared with December 31, 2016, cash rose from $14,679 and working-capital deficit narrowed from $1,137,470. Management cited the January equity raise, operating cash generation, payment of the $200,000 class-action settlement, and lower accrued executive compensation as factors affecting liquidity.
- The company says additional funding is needed for platform expansion, working capital, and debt obligations. It estimated general and administrative and working-capital requirements of approximately $2,425,000 for the next 12 months. It expects to seek further capital but gives no assurance of financing or positive cash flow; no specific revenue or earnings guidance is provided.
- The filing states that recurring operating losses and funding needs raise substantial doubt about the company’s ability to continue as a going concern. Management’s ability to raise capital and achieve profitable operations is central to that assessment.
- In June/July 2017, the company repaid a $250,000 note and arranged replacement three-year, 6% loans from entities or individuals associated with directors and controlling stockholders. Related-party transactions and outstanding management wages warrant attention.
- A previously disclosed junk-fax class action was settled for $200,000 and funded in March 2017; the filing reports no legal proceedings in Part II. No off-balance-sheet arrangements were reported. Disclosure controls and procedures were deemed ineffective; no material change in internal control over financial reporting was reported.
Important facts to verify
- Confirm the issuer identity: the supplied filing is for Trxade Group, Inc., not Scienture Holdings, Inc.
- Reconcile reported general and administrative expense: the financial statements show $1,906,692 for nine months, while MD&A separately presents $1,684,640 of general and administrative expense plus $222,052 of warrant and option expense.
- Review debt maturities, related-party terms and guarantees, and the company’s ability to refinance or repay obligations.
- Assess whether available cash and anticipated financing can cover the stated $2,425,000 next-12-month expense and working-capital estimate, given negative working capital and the going-concern warning.
- Consider potential dilution from outstanding warrants, options, and future equity financing; 31,985,827 common shares were outstanding at November 6, 2017.